Search Results - "Halfdanarson, T. R."

Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival by Halfdanarson, T.R., Rabe, K.G., Rubin, J., Petersen, G.M.

“…Pancreatic neuroendocrine tumors (PNETs) are uncommon neoplasms that can present with symptoms of hormone overproduction. We evaluated the incidence,…”
Get full text

Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial by Welsh, J. L., Wagner, B. A., van’t Erve, T. J., Zehr, P. S., Berg, D. J., Halfdanarson, T. R., Yee, N. S., Bodeker, K. L., Du, J., Roberts, L. J., Drisko, J., Levine, M., Buettner, G. R., Cullen, J. J.

“…Background Treatment for pancreatic cancer with pharmacological ascorbate (ascorbic acid, vitamin C) decreases tumor progression in preclinical models. A phase…”
Get full text

A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy by Halfdanarson, TR, Markovic, SN, Kalokhe, U, Luppi, M

Get full text

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm by Haddox, C.L., Shenoy, N., Shah, K.K., Kao, J.C., Jain, S., Halfdanarson, T.R., Wijdicks, E.F., Goetz, M.P.

Get full text

Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors by Halfdanarson, Thorvardur R, Rubin, Joseph, Farnell, Michael B, Grant, Clive S, Petersen, Gloria M

“…Pancreatic endocrine tumors (PETs) are uncommon tumors with an annual incidence <1 per 100 000 person-years in the general population. The PETs that produce…”
Get full text

Extra-hepatic hepatocellular carcinoma presenting as obstructive jaundice by Batsis, J.A., Halfdanarson, T.R., Pitot, H.

“…Hepatocellular carcinoma is a neoplasm with a uniformly poor prognosis. Risk factors for its development include chronic hepatitis B or C infection,…”
Get full text

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium by Khaki, A.R., Wise-Draper, T.M., French, B., Hennessy, C., Hsu, C.-Y., Shyr, Y., Painter, C.A., Peters, S., Rini, B.I., Mishra, S., Rivera, D.R., Acoba, J.D., Bashir, B., Bekaii-Saab, T., Berg, S., Bernicker, E.H., Bilen, M.A., Bindal, P., Bishnoi, R., Bouganim, N., Bowles, D.W., Cabal, A., Caimi, P.F., Crowell, J., Desai, A., Dixon, B., Doroshow, D.B., Durbin, E.B., Farmakiotis, D., Fazio, A., Fecher, L.A., Friese, C.R., Fu, J., Gadgeel, S.M., Glover, M.J., Goyal, S., Grover, P., Gulati, S., Gupta, S., Halabi, S., Halfdanarson, T.R., Halmos, B., Hausrath, D.J., Hawley, J.E., Hsu, E., Jani, C., Jayaraj, A., Johnson, D.B., Kasi, A., Khan, H., Kuderer, N.M., Kwon, D.H., Li, A., Loaiza-Bonilla, A., Low, C.A., Lustberg, M.B., Lyman, G.H., McKay, R.R., McNair, C., Menon, H., Mesa, R.A., Mundt, D., Nagaraj, G., Nakasone, E.S., Nizam, A., Nock, N.L., Patel, J.M., Patel, K.G., Peddi, P., Pennell, N.A., Piper-Vallillo, A.J., Puc, M., Reeves, M.E., Reuben, D.Y., Rosovsky, R.P., Salazar, M., Schmidt, A.L., Schwartz, G.K., Shah, M.R., Shah, S.A., Shah, C., Shaya, J.A., Stockerl-Goldstein, K.E., Streckfuss, M., Subbiah, S., Tachiki, L., Thakkar, A., Tucker, M.D., Verma, A.K., Vinh, D.C., Weiss, M., Wu, J.T., Wulff-Burchfield, E., Xie, Z., Yu, P.P., Zhou, A.Y., Zhu, H., Zubiri, L., Warner, J.L., Lopes, GdL

“…Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort…”
Get full text

The impact of peptide receptor radionucleotide therapy with Lutetium-177 DOTATATE on cardiac metastases in neuroendocrine tumors by Scalia, I, Sonbol, B, Farina, J M, Pereyra, M, Wang, Y, Bekaii-Saab, T S, Yang, M, Connolly, H M, Pellikka, P A, Herrmann, J, Halfdanarson, T R, Starr, J S, Luis, A S, Arsanjani, R, Ayoub, C

“…Abstract Background Cardiac metastasis from neuroendocrine tumors (NET) is rare and has been thought to potentially result in life threatening sequalae…”
Get full text

533PDBACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study by Mettu, N B, Twohy, E, Ou, F-S, Halfdanarson, T R, Lenz, H J, Breakstone, R, Boland, P M, Crysler, O, Wu, C, Grothey, A, Nixon, A B, Bolch, E, Niedzwiecki, D, Fruth, B, Schweitzer, B, Elsing, A, Hurwitz, H, Fakih, M G, Bekaii-Saab, T

“…Abstract Background The benefit of immune checkpoint blockade in mCRC is currently limited to mismatch repair (MMR) deficient tumours. Increasing evidence…”
Get full text

Survival analyses of pancreatic neuroendocrine tumors: Contrasting institutional databases with population-based studies by Strosberg, J. R., Halfdanarson, T. R.

“…Abstract only 186 Background: Prognostic data in pancreatic neuroendocrine tumors derives from population-based studies as well as from institutional…”
Get full text

Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs) by Gutierrez, M.E., Giaccone, G., Liu, S.V., Rajan, A., Guha, U., Halfdanarson, T.R., Curtis, K.K., Kunz, P.L., Gabrail, N., Hinson, J.M., Orlemans, E.O.

Get full text

High-grade neuroendocrine carcinoma of the uterine cervix: Outcomes and the role of chemotherapy by Naraev, B., Goodheart, M. J., O'Dorisio, T. M., Halfdanarson, T. R.

“…Abstract only…”
Get full text

Veterans' Continued Participation in an Annual Fecal Immunochemical Test Mailing Program for Colorectal Cancer Screening by Schlichting, Jennifer A, Mengeling, Michelle A, Makki, Nader M, Malhotra, Ashish, Halfdanarson, Thorvardur R, Klutts, J Stacey, Levy, Barcey T, Kaboli, Peter J, Charlton, Mary E

“…The objective of this study was to determine what proportion of veterans previously screened for colorectal cancer (CRC) using fecal immunochemical testing…”
Get full text

Pancreatic endocrine tumors (PETs): Incidence and recent trend toward improved survival by Halfdanarson, T. R., Rabe, K., Rubin, J., Petersen, G. M.

“…Abstract only 4584 Background: PETs (islet cell tumors) are uncommon and often indolent tumors, but little is known about the incidence of PETs in the US and…”
Get full text

Incretins and risk of neoplasia by Halfdanarson, Thorvardur R, Pannala, Rahul

“…An association exists but causality has not yet been proved…”
Get full text

Relationship of HER2 overexpression to brain metastasis (BM) in esophageal cancer (EC) patients by Abu Hejleh, T., DeYoung, B., Engelman, E. S., Deutsch, J., Zimmerman, M. B., Halfdanarson, T. R., Berg, D. J., Parekh, K., Lynch, W., Iannettoni, M., Bhatia, S., Clamon, G. H.

“…Abstract only…”
Get full text

Small bowel adenocarcinoma: A review of 491 cases by Halfdanarson, T. R., Quevedo, F., McWilliams, R. R.

“…Abstract only 4127 Background: Small bowel adenocarcinoma (SBA) is a rare tumor accounting for less than 2% of all GI tumors. The prognosis of advanced disease…”
Get full text

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm by Haddox, C L, Shenoy, N, Shah, K K, Kao, J C, Jain, S, Halfdanarson, T R, Wijdicks, E F, Goetz, M P

Get full text

A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy by Halfdanarson, T R, Markovic, S N, Kalokhe, U, Luppi, M

Get full text